Ectopic PLAG1 induces muscular dystrophy in the mouse.

[1]  N. Sulaiman,et al.  A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review , 2022, Frontiers in Bioengineering and Biotechnology.

[2]  T. Singh,et al.  Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy. , 2021, European journal of pharmacology.

[3]  J. Mendell,et al.  Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New. , 2021, Seminars in pediatric neurology.

[4]  J. Jensen,et al.  Key Genes Regulating Skeletal Muscle Development and Growth in Farm Animals , 2021, Animals : an open access journal from MDPI.

[5]  C. Angelini.  LGMD. Identification, description and classification , 2020, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[6]  K. Anthony,et al.  The Duchenne muscular dystrophy gene and cancer , 2020, Cellular Oncology.

[7]  P. Delafontaine,et al.  Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy , 2020, Cells.

[8]  B. Wong,et al.  Recombinant human insulin‐like growth factor‐1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy , 2020, Muscle & nerve.

[9]  L. Milanesi,et al.  Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy , 2019, EMBO molecular medicine.

[10]  R. Butterfield.  Congenital Muscular Dystrophy and Congenital Myopathy. , 2019, Continuum.

[11]  J. Glennon,et al.  Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1 , 2019, Front. Neurol..

[12]  D. Rakheja,et al.  Bayesian Modeling Identifies PLAG1 as a Key Regulator of Proliferation and Survival in Rhabdomyosarcoma Cells , 2019, Molecular Cancer Research.

[13]  Huijiang Gao,et al.  Genome-wide association study identifies the PLAG1-OXR1 region on BTA14 for carcass meat yield in cattle. , 2019, Physiological genomics.

[14]  A. Ferrari,et al.  Rhabdomyosarcoma , 2019, Nature Reviews Disease Primers.

[15]  J. Mendell,et al.  Mutations in microRNA processing genes in Wilms tumors derepress the IGF2 regulator PLAG1 , 2018, Genes & development.

[16]  Eric T. Wang,et al.  Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes. , 2017, Current opinion in genetics & development.

[17]  T. Cooper,et al.  Extensive alternative splicing transitions during postnatal skeletal muscle development are required for calcium handling functions , 2017, bioRxiv.

[18]  M. Girgenrath,et al.  IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophy. , 2016, Human molecular genetics.

[19]  V. Rotter,et al.  p53 on the crossroad between regeneration and cancer , 2016, Cell Death and Differentiation.

[20]  L. Kunkel,et al.  The Pathogenesis and Therapy of Muscular Dystrophies. , 2015, Annual review of genomics and human genetics.

[21]  R. Griggs,et al.  Advances in Muscular Dystrophies. , 2015, JAMA neurology.

[22]  E. Clementi,et al.  Skeletal Muscle Homeostasis in Duchenne Muscular Dystrophy: Modulating Autophagy as a Promising Therapeutic Strategy , 2014, Front. Aging Neurosci..

[23]  M. van de Rijn,et al.  Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs , 2014, Nature Genetics.

[24]  Hongkyun Kim,et al.  Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy , 2013, Proceedings of the National Academy of Sciences.

[25]  P. Soler-Palacín,et al.  Complement factor I deficiency: a not so rare immune defect. Characterization of new mutations and the first large gene deletion , 2012, Orphanet Journal of Rare Diseases.

[26]  S. Hammond,et al.  Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53‐deficient mice , 2012, The Journal of pathology.

[27]  S. Pandya,et al.  Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. , 2011, Archives of neurology.

[28]  K. Sakiyama,et al.  Expression of HGF and IGF-1 during regeneration of masseter muscle in mdx mice , 2010, Journal of Muscle Research and Cell Motility.

[29]  Livija Medne,et al.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.

[30]  Wendy S. Beane,et al.  Regeneration: The origin of cancer or a possible cure? , 2009, Seminars in cell & developmental biology.

[31]  J. Chamberlain,et al.  Dystrophin‐deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  C. Dogra,et al.  Regulation of phosphatidylinositol 3‐kinase (PI3K)/Akt and nuclear factor‐kappa B signaling pathways in dystrophin‐deficient skeletal muscle in response to mechanical stretch , 2006, Journal of cellular physiology.

[33]  Angela K. Peter,et al.  Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. , 2006, Experimental cell research.

[34]  W. V. D. Van de Ven,et al.  Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression. , 2005, Cancer research.

[35]  W. V. D. Van de Ven,et al.  Targeted disruption of the murine Plag1 proto‐oncogene causes growth retardation and reduced fertility , 2004, Development, growth & differentiation.

[36]  R. Kuick,et al.  Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma , 2004, Genes, chromosomes & cancer.

[37]  B. Moor,et al.  Microarray screening for target genes of the proto-oncogene PLAG1 , 2004, Oncogene.

[38]  A. Musarò,et al.  Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice , 2002, The Journal of cell biology.

[39]  G. Lynch,et al.  IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice , 2001, Neuromuscular Disorders.

[40]  J. Smith,et al.  IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death , 2000, Cell Death and Differentiation.

[41]  J. Mark,et al.  Evidence of involvement of the PLAG1 gene in lipoblastomas. , 2000, International journal of oncology.

[42]  C. Kahn,et al.  A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. , 1998, Molecular cell.

[43]  K. Kas,et al.  Promoter swapping between the genes for a novel zinc finger protein and β-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations , 1997, Nature Genetics.

[44]  D. Shotton,et al.  Muscular dystrophy in the mdx mouse: Histopathology of the soleus and extensor digitorum longus muscles , 1987, Journal of the Neurological Sciences.

[45]  Karen S. Fernández,et al.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. , 2010, The American journal of pathology.